News
Brazil Suspends Trials Of Chinese Covid-19 Vaccine Due To Adverse Incident
Brazil’s health regulator halted clinical trials of the potential coronavirus vaccine CoronaVac, citing an adverse, serious event, according to a statement it posted to its website Monday night.
The potential vaccine is being developed by Chinese biopharmaceutical firm Sinovac and...
Clinical Trials
Cancer Treatment Can Be Cloned For COVID-19
As per the recent international study by the scientists from Italy & Australia, Beta-blockers have it in them to be a potential treatment for COVID-19.
The scientists are now calling for Clinical Trials to support the research findings. Dr. Nirmal...
News
A New Senate & its implications on The Pharmaceutical Sector?
The US elections make big news whenever they occur. The fact that who comes to power has a phenomenal effect on all industries, big or small. One such industry that is bracing for the impact is the Pharmaceutical Sector....
News
AstraZeneca Says Calquence Approved In The EU For CLL
AstraZeneca’s Calquence (acalabrutinib), a next-generation selective Bruton’s tyrosine kinase (BTK) inhibitor, has been approved in the European Union (EU) for the treatment of adult patients with chronic lymphocytic leukaemia (CLL), the most common type of leukaemia in adults.
The approval...
News
Novavax COVID-19 Vaccine Granted Fast Track Designation by U.S. FDA
Novavax, Inc., a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, announced that the U.S. FDA has granted Fast Track Designation for NVX-CoV2373, the Company’s COVID-19 vaccine candidate. Currently in late-phase clinical development, NVXCoV2373 is a stable,...
News
Llama nanobodies could be a powerful weapon against COVID-19
The researchers at the University of Pittsburgh School of Medicine describe a new method to extract tiny but extremely powerful SARS-CoV-2 antibody fragments from llamas, which could be fashioned into inhalable therapeutics with the potential to prevent and treat...
Drug Research
Oxford Biomedica and PhoreMost enter gene therapy discovery collaboration
Oxford Biomedica plc , a leading gene and cell therapy group and PhoreMost Limited, the UK-based biopharmaceutical company dedicated to developing drugs against intractable disease targets, announced that they have entered into a discovery collaboration to develop next-generation CAR-T...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read